Synthetic lethality

Anticancer Bioscience Presenting at Biotech Showcase(TM) Digital 2021 Showcasing its Synthetic Lethal Precision Oncology Pipeline for the First Time

Wednesday, January 13, 2021 - 2:34pm

Chengdu, China--(Newsfile Corp. - January 13, 2021) - Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today announced that it is participating in Biotech Showcase Digital 2021, for the first time, providing an on-demand company presentation.

Key Points: 
  • Chengdu, China--(Newsfile Corp. - January 13, 2021) - Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today announced that it is participating in Biotech Showcase Digital 2021, for the first time, providing an on-demand company presentation.
  • Anticancer Bioscience is participating in Biotech Showcase Digital 2021.
  • The Company will showcase its pioneering approach to precision oncology, and how it is applying its synthetic lethality expertise for better cancer therapies.
  • Pioneers in synthetic lethal approaches to precision oncology and experts in MYC biology and cell division, ACB was founded in 2016 in Chengdu, China.

IDEAYA Biosciences Announces Submission of IND Application for MAT2A Development Candidate IDE397 with the U.S. FDA

Monday, January 11, 2021 - 11:00am

"The IDE397 IND submission is an important milestone for IDEAYA as we advance our broader synthetic lethality pipeline of potential first-in-class therapies.

Key Points: 
  • "The IDE397 IND submission is an important milestone for IDEAYA as we advance our broader synthetic lethality pipeline of potential first-in-class therapies.
  • IDE397 was discovered through our efforts to develop a potential best-in-class MAT2A inhibitor, and we have achieved our target product profile," saidMichael Dillon, Ph.D., Chief Scientific Officer,IDEAYA Biosciences.
  • IDEAYABiosciences will present a program update on IDE397 and its broader synthetic lethality pipeline at the 39th Annual J.P. Morgan Healthcare Conference.
  • IDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.

Cellworks CBM Identifies Genomic Signatures Impacting HOXA Regulation that Determine Response for AML Patients with Monosomy 7

Monday, December 7, 2020 - 4:00pm

Cellworks Omics Biology Model (CBM) analysis can identify genetic signatures associated with therapy response and non-response for AML patients with Monosomy 7 in advance of treatment, which in turn can inform therapy planning and improve patient outcomes.

Key Points: 
  • Cellworks Omics Biology Model (CBM) analysis can identify genetic signatures associated with therapy response and non-response for AML patients with Monosomy 7 in advance of treatment, which in turn can inform therapy planning and improve patient outcomes.
  • Cellworks CBM analysis identified other genomic alterations that determine chemotherapy response, which can enable a personalized approach to therapy.
  • Cellworks CBM analysis identified other genomic alterations that determine chemotherapy response, including DNA repair deficiency genes, mismatch repair (MMR), and homologous recombination repair (HRR) genes.
  • On the other hand, Cellworks CBM analysis identified genetic signatures associated with a 100% remission rate from AML induction therapy despite the presence of (-7).

IDEAYA Announces Partnership With The Broad Institute And Advancement Of Synthetic Lethality Programs And Platform

Thursday, October 22, 2020 - 11:00am

The IDEAYA partnership with the laboratory of William R. Sellers, M.D., Core Institute Member, Broad Institute, will utilize the CRISPR paralog screening platform developed at the Broad Institute to evaluate functionally redundant paralogous genesacross ovarian cancer subtypes and to generate novel Synthetic Lethality (SL) based target and biomarker discoveries.

Key Points: 
  • The IDEAYA partnership with the laboratory of William R. Sellers, M.D., Core Institute Member, Broad Institute, will utilize the CRISPR paralog screening platform developed at the Broad Institute to evaluate functionally redundant paralogous genesacross ovarian cancer subtypes and to generate novel Synthetic Lethality (SL) based target and biomarker discoveries.
  • In addition to its three GSK-partnered Synthetic Lethality programs in MAT2A, Pol Theta and Werner Helicase, IDEAYA has several wholly owned SL and DNA Damage Target (DDT) programs, including PARG and multiple additional SL / DDT preclinical programs.
  • "We are executing on our strategy to build the industry leading Synthetic Lethality focused biotechnology company, including through strategic partnerships.
  • The Broad and earlier announced GSK partnership advances our efforts to extend our research leadership in Synthetic Lethality and to build a diverse pipeline of potential first-in-class Synthetic Lethality programs," said Yujiro S. Hata, President and CEO, IDEAYA Biosciences.

Rain Therapeutics Announces License Agreement for the Development of Proprietary RAD52 Inhibitors in the DNA Damage Response Pathway

Tuesday, August 25, 2020 - 1:00pm

RAD52 is a novel and rational oncology target, and weve been very impressed with the advances in the field made by Drexel researchers.

Key Points: 
  • RAD52 is a novel and rational oncology target, and weve been very impressed with the advances in the field made by Drexel researchers.
  • RAD52 is involved in several DDR pathways, and RAD52 inactivation is synthetically lethal in cancer cells with BRCA1/2 and other homologous recombination (HR) gene mutations.
  • Drexels RAD52-targeted inhibitors have evidenced potent in vitro and in vivo activity in BRCA1-deficient xenograft models, alone and in combination with PARP inhibitors.
  • Drexel University will also receive milestone payments and royalties based on successful development and commercialization of proprietary programs.

Repare Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Trial of RP-3500

Wednesday, July 29, 2020 - 11:00am

The primary outcome measure in the Phase 1 part of the study will be an assessment of safety and tolerability and determination of a dose for the Phase 2 portion of the trial.

Key Points: 
  • The primary outcome measure in the Phase 1 part of the study will be an assessment of safety and tolerability and determination of a dose for the Phase 2 portion of the trial.
  • The Phase 2 monotherapy portion of the trial is expected to further evaluate the efficacy of RP-3500 in biomarker-selected tumors.
  • Talazoparib is being provided by Pfizer to Repare for the purposes of the clinical trial.
  • Repare Therapeutics is a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.

Cyteir Therapeutics Advances Clinical Trial of Lead RAD51 Synthetic Lethality Program in Cancer and Expands Senior Leadership Team

Tuesday, July 7, 2020 - 1:40pm

Additionally, the company announced the appointment of three senior executives, all with extensive pharmaceutical and biotechnology leadership experience.

Key Points: 
  • Additionally, the company announced the appointment of three senior executives, all with extensive pharmaceutical and biotechnology leadership experience.
  • Inhibiting RAD51-mediated homologous recombination in these cancer cells limits their ability to self-repair, leading to overwhelming DNA damage and ultimately, self-destruction a therapeutic effect known as synthetic lethality.
  • These findings support the broad potential for CYT-0851 to address the high unmet clinical need across various cancers and stages.
  • Cyteir Therapeutics, Cyteir, and associated logos are trademarks of Cyteir Therapeutics, Inc.

IDEAYA Appoints Garret Hampton, Ph.D., to the Board of Directors, an Industry Leader in Precision Medicine Oncology and Diagnostics

Tuesday, June 30, 2020 - 11:00am

Through these roles, Dr. Hampton has become a thought leader in the area of precision medicine oncology, including next generation sequencing, cancer genomics, and companion diagnostics.

Key Points: 
  • Through these roles, Dr. Hampton has become a thought leader in the area of precision medicine oncology, including next generation sequencing, cancer genomics, and companion diagnostics.
  • IDEAYA believes global access to molecular diagnostics for oncology patients, particularly in Asia, is key to the development of targeted oncology medicines.
  • "IDEAYA is a leader in Synthetic Lethality, an emerging field of precision medicine oncology.
  • IDEAYA is applying these capabilities across multiple classes of precision medicine, including synthetic lethality which represents an emerging class of precision medicine targets.

Industrial-Scale Phenotyping of Cell-Cycle Control in Yeast

Tuesday, May 26, 2020 - 1:32pm

By focusing their attention on the inner workings of yeast, scientists have made remarkable progress in learning how cells control cell division and growth.

Key Points: 
  • By focusing their attention on the inner workings of yeast, scientists have made remarkable progress in learning how cells control cell division and growth.
  • Synthetic lethal mutations arise when viable yeast cells carrying deletions of two different genes are crossed to produce double-mutant cells that are unable to grow and survive.
  • Genetic interactions derived from high-throughput phenotyping of 6589 yeast cell cycle mutants.
  • The GenoFAB Automation Platform accelerates biomedical research projects by connecting laboratory operations with data services and supply chain transactions.

IDEAYA Biosciences to Participate in Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020

Tuesday, May 19, 2020 - 11:00am

IDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.

Key Points: 
  • IDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.
  • IDEAYA is applying these capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality which represents an emerging class of precision medicine targets.
  • This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events.
  • IDEAYA undertakes no obligation to update or revise any forward-looking statements.